Syneron's VelaShape® III Wins the 1st Anti-Aging & Beauty Trophy in the Non-Invasive Body Shaping Category
PARIS, Oct. 14, 2013 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today that its VelaShape® III system won the 1st Anti-Aging & Beauty Trophy in the category of NON-INVASIVE BODY SHAPING TECHNOLOGIES awarded at the 1st Anti-Aging Medicine European Congress (AMEC) in Paris, France.
The award was in recognition of those companies who strive to develop innovative products or technologies in the field of aesthetic and anti-aging medicine and was presented by Euromedicom and the WOSIAM (World Society Interdisciplinary Anti-Aging Medicine), in partnership with the prestigious French and international media partners. The jury included representatives from the AMEC 2013 scientific committee, clinicians, journalists and bloggers.
Shimon Eckhouse, Ph.D, the Founder and CEO of Syneron Medical, was personally present to accept the award. "We're delighted to be one of the first to be recognized for this prestigious award," said Dr. Eckhouse. "Together with our physician partners and engineers, we designed a sophisticated, innovative body shaping platform that delivers visible outcomes in as little as a single treatment. The VelaShape III answers our customers' needs and leads the non-invasive body shaping category to the next level."
VelaShape III is the latest revolution of non-invasive body shaping device introduced by Syneron Medical. Powered by Syneron's proprietary elos® technology, VelaShape III employs a combination of modalities including infra-red light, bi-polar radio frequency and vacuum to effectively and precisely manipulate and heat the tissue for optimal non-invasive body sculpting, body shaping and cellulite treatment. This powerful system comes equipped with Syneron's proprietary Smart RF™, ensuring consistent and predictable clinical results. All this, packaged in a state-of-the-art, sleek industrial design.
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical makes with the SEC. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
SOURCE Syneron Medical Ltd.
More by this Source
Syneron Receives US FDA Clearance to Market the UltraShape System for Fat Cell Destruction
Apr 14, 2014, 09:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.